S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
NASDAQ:SRRA

Sierra Oncology Stock Forecast, Price & News

$20.73
-0.20 (-0.96 %)
(As of 10/19/2021 11:12 AM ET)
Add
Compare
Today's Range
$20.27
$20.73
50-Day Range
$18.91
$23.10
52-Week Range
$12.02
$23.85
Volume130 shs
Average Volume36,361 shs
Market Capitalization$260.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
30 days | 90 days | 365 days | Advanced Chart
Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.


Sierra Oncology logo

About Sierra Oncology

Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
Employees
69
Year Founded
N/A

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$8.87 per share

Profitability

Net Income
$-80.90 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$260.39 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.40 out of 5 stars

Medical Sector

179th out of 1,361 stocks

Pharmaceutical Preparations Industry

77th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

Is Sierra Oncology a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sierra Oncology stock.
View analyst ratings for Sierra Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Sierra Oncology?

Wall Street analysts have given Sierra Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sierra Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sierra Oncology?

Sierra Oncology saw a increase in short interest in September. As of September 30th, there was short interest totaling 78,000 shares, an increase of 201.2% from the September 15th total of 25,900 shares. Based on an average daily trading volume, of 58,100 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.8% of the company's shares are short sold.
View Sierra Oncology's Short Interest
.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sierra Oncology
.

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) announced its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.62) by $0.05.
View Sierra Oncology's earnings history
.

How has Sierra Oncology's stock been impacted by COVID-19 (Coronavirus)?

Sierra Oncology's stock was trading at $11.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SRRA shares have increased by 78.7% and is now trading at $20.73.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SRRA?

4 analysts have issued 1 year target prices for Sierra Oncology's shares. Their forecasts range from $27.00 to $33.00. On average, they anticipate Sierra Oncology's share price to reach $29.67 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price.
View analysts' price targets for Sierra Oncology
or view top-rated stocks among Wall Street analysts.

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the following people:
  • Stephen George Dilly, President, Chief Executive Officer & Director
  • Emma McCann, SVP-Operations & Program Management
  • Sukhi Jagpal, Chief Financial Officer
  • Mark M. Kowalski, Chief Medical Officer
  • Diane Gardiner, Senior VP-Human Resources & Administration

What other stocks do shareholders of Sierra Oncology own?

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $20.73.

How much money does Sierra Oncology make?

Sierra Oncology has a market capitalization of $260.39 million and generates $300,000.00 in revenue each year. The biotechnology company earns $-80.90 million in net income (profit) each year or ($7.70) on an earnings per share basis.

How many employees does Sierra Oncology have?

Sierra Oncology employs 69 workers across the globe.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is www.sierraoncology.com.

Where are Sierra Oncology's headquarters?

Sierra Oncology is headquartered at 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at (604) 558-6536 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.